Please enter verification code
Confirm
Review Article: Xanthine Oxidoreductase-An Important Functional Component of Differentiation, Apoptosis and Aggressiveness of Tumors
Cell Biology
Volume 4, Issue 4, July 2016, Pages: 24-30
Received: Sep. 29, 2016; Accepted: Nov. 5, 2016; Published: Dec. 17, 2016
Views 3746      Downloads 174
Authors
Yinghong Zhang, Department of Nursing, Wuhan University of Science and Technology, Wuhan, China
Hong Cheng, Department of Nursing, Wuhan University of Science and Technology, Wuhan, China
Jing Xu, Department of Nursing, Wuhan University of Science and Technology, Wuhan, China
Lan Lu, Department of Nursing, Wuhan University of Science and Technology, Wuhan, China
Article Tools
Follow on us
Abstract
Xanthine oxidoreductase(XOR)plays an important role in many pathologies, such as tumors, chronic hypoxia, renal injury, hypertension and so on. In this article we mainly review the current research about the regulation of activity and gene expression of XOR, and its physiochemical property, organ distribution, changes in tumors and relation with the other diseases. We conclude that XOR is an important functional component of differentiation and apoptosis and diminished expression contributes to aggressiveness of tumors.
Keywords
Xanthine Oxidoreductase, Differentiation, Apoptosis, Aggressiveness, Tumors
To cite this article
Yinghong Zhang, Hong Cheng, Jing Xu, Lan Lu, Review Article: Xanthine Oxidoreductase-An Important Functional Component of Differentiation, Apoptosis and Aggressiveness of Tumors, Cell Biology. Vol. 4, No. 4, 2016, pp. 24-30. doi: 10.11648/j.cb.20160404.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Kuwabara Y, Nishino T, Okamoto K, Matsumura T, Eger BT, Pai EF, Nishino T. Unique amino acids cluster for switching from the dehydrogenase to oxidase form of xanthine oxidoreductase. Proc Natl Acad Sci U S A, 2003.100 (14): 8170-75.
[2]
Cristofer Enroth, Bryan T. Eger, Ken Okamoto, Tomoko Nishino, Takeshi Nishino, Emil F. Pai. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Proc Natl Acad Sci USA 2000. 97(20): 10723-28.
[3]
Correia MA, Otrelo-Cardoso AR, Schwuchow V, Sigfridsson Clauss KG, Haumann M, Romão MJ, Leimkühler S, Santos-Silva T. The Escherichia coli Periplasmic Aldehyde Oxidoreductase Is an Exceptional Member of the Xanthine Oxidase Family of Molybdoenzymes. ACS Chem Biol. 2016. [Epub ahead of print]
[4]
Cantu-Medellin, N. and E. E. Kelley, Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation. Redox Biol 2013. 1: 353-58.
[5]
Huang CC, Chen KL, Cheung CH, Chang JY. Autophagy induced by cathepsin S inhibition induces early ROS production, oxidative DNA damage, and cell death via xanthine oxidase. Free Radic Biol Med 2013.65:1473-86.
[6]
Junji Lin, Ping Xu, Patricia LaVallee, John R. Hoidal. Identification of Proteins Binding to E-Box/Ku86 Sites and Function of the Tumor Suppressor SAFB1 in Transcriptional Regulation of the Human Xanthine Oxidoreductase Gene. J Biol Chem 2008.283(44): 29681-89.
[7]
Ken Okamoto, Teruo Kusano, Takeshi Nishino. Chemical Nature and Reaction Mechanisms of the Molybdenum Cofactor of Xanthine Oxidoreductase. Curr Pharm Des 2013.19(14): 2606–14.
[8]
Battelli, M. G., A. Bolognesi, and L. Polito, Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. Biochim Biophys Acta 2014.1842(9): 1502-17.
[9]
Chris A. Pritsos. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact. 2000.129(1-2):195-208.
[10]
Harrison, R. Physiological roles of xanthine oxidoreductase. Drug Metab Rev 2004.36(2): 363-75.
[11]
Harrison R. Structure and function of xanthine oxidoreductase: where are we now? Free Radic Biol Med. 2002.33(6):774-97.
[12]
Mika Sakela, Risto Lapatto, Kari O. Raivio. Irreversible convention of xanthine dehydrogenase into xanthine oxidase by a mitochondrial protease. FEBS Letter1999. 443:117-120.
[13]
Engerson, T. D., et al., Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. J Clin Invest, 1987. 79(6): p. 1564-70.
[14]
Kelley, E. E., et al., Hydrogen peroxide is the major oxidant product of xanthine oxidase. Free Radic Biol Med, 2010. 48(4): p. 493-8.
[15]
Nishino, T., et al., The C-terminal peptide plays a role in the formation of an intermediate form during the transition between xanthine dehydrogenase and xanthine oxidase. FEBS J, 2015. 282(16): p. 3075-90.
[16]
EAMONN J. DUKE, PADDY JOYCE and J. PHILIP RYAN. Characterization of Alternative Molecular Forms of Xanthine Oxidase in the Mouse. Biochem. J. 1973.131, 187-190.
[17]
Sarnesto A, Linder N, Raivio KO. Organ distribution and molecular forms of human xanthine dehydrogenase/xanthine oxidase protein. Lab Invest. 1996.74(1):48-56.
[18]
FRED LACY, DAVID A. GOUGH, and GEERT W. SCHMID-SCH¨ONBEIN. ROLE OF XANTHINE OXIDASE IN HYDROGEN PEROXIDE PRODUCTION. Free Radical Biology & Medicine, 1998. 25 (6), pp. 720–27.
[19]
Cook W, Chu R, Saksela M, Raivio K, Yeldandi A. Differential immunohistochemical localization of xanthine oxidase in normal and neoplastic human breast epithelium. Int J Oncol. 1997.11(5):1013-7.
[20]
Richard, W. Topham, and Melissa, LIVER XANTHINE DEHYDROGENASE AND IRON MOBILIZATION. 8lOCHEMlCAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1982. 109(4): p. 1240-12046.
[21]
Richard W. Topham, M.C.W., Melissa P. Calisch, and R. Wayne Williams, Evidence for the Participation of Intestinal Xanthine Oxidase in the Mucosal Processing of Iron7. Biochemistry 1982. 21: p. 4529-4535.
[22]
Young-Ran Lim, In-Hyeok Kim, Songhee Han, Hyoung-Goo Park, Mi-Jung Ko, Young-Jin Chun, Chul-Ho Yun, Donghak Kim. Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A2*8, *15, and *16 (R456H, P42R, and R377Q). Biomol Ther (Seoul) 2015. 23(2): 189–194.
[23]
Malemud, C. J., et al., Monosodium Urate and Tumor Necrosis Factor-alpha Increase Apoptosis in Human Chondrocyte Cultures. Rheumatology (Sunnyvale), 2012. 2: p. 113.
[24]
Seymour, K. J., et al., Stress activation of mammary epithelial cell xanthine oxidoreductase is mediated by p38 MAPK and CCAAT/enhancer-binding protein-beta. J Biol Chem, 2006. 281(13): p. 8545-58.
[25]
Mostefai, H. A., et al., Phosphatidylinositol 3-Kinase and Xanthine Oxidase Regulate Nitric Oxide and Reactive Oxygen Species Productions by Apoptotic Lymphocyte Microparticles in Endothelial Cells. The Journal of Immunology, 2008. 180(7): p. 5028-5035.
[26]
Asai, R., et al., Two mutations convert mammalian xanthine oxidoreductase to highly superoxide-productive xanthine oxidase. J Biochem, 2007. 141(4): p. 525-34.
[27]
Yamaguchi, Y., et al., Human xanthine oxidase changes its substrate specificity to aldehyde oxidase type upon mutation of amino acid residues in the active site: roles of active site residues in binding and activation of purine substrate. J Biochem, 2007. 141(4): p. 513-24.
[28]
Andrea SCHIEBER and Dale E. EDMONDSON. Studies on the induction and phosphorylation of xanthine dehydrogenase in cultured chick embryo hepatocytes. Eur. J. Biochem. 1993, 215, 307-314.
[29]
Peleli M, Zollbrecht C, Montenegro MF, Hezel M, Zhong J, Persson EG, Holmdahl R, Weitzberg E, Lundberg JO, Carlström M. Enhanced XOR activity in eNOS-deficient mice: Effects on the nitrate-nitrite-NO pathway and ROS homeostasis.Free Radic Biol Med. 2016,99:472-484.
[30]
Junji Lin, Ping Xu, Patricia LaVallee, John R. Hoidal. Identification of Proteins Binding to E-Box/Ku86 Sites and Function of the Tumor Suppressor SAFB1 in Transcriptional Regulation of the Human Xanthine Oxidoreductase Gene. J Biol Chem. 2008. 283(44): 29681–29689.
[31]
Nanduri, J., et al., Xanthine oxidase mediates hypoxia-inducible factor-2alpha degradation by intermittent hypoxia. PLoS One, 2013. 8(10): p. e75838.
[32]
Nina Linder, Johan Lundin, Jorma Isola, Mikael Lundin, KariO. Raivio, and Heikki Joensuu. Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer. Clin Cancer Res 2005. 11(12):4372-4381.
[33]
Linder, N., et al., Decreased xanthine oxidoreductase is a predictor of poor prognosis in early-stage gastric cancer. J Clin Pathol, 2006. 59(9): p. 965-71.
[34]
Linder, N., et al., Xanthine oxidoreductase - clinical significance in colorectal cancer and in vitro expression of the protein in human colon cancer cells. Eur J Cancer, 2009. 45(4): p. 648-55.
[35]
Kim, A. W., et al., Prognostic value of xanthine oxidoreductase expression in patients with non-small cell lung cancer. Lung Cancer, 2011. 71(2): p. 186-90.
[36]
Linder, N., et al., Decreased xanthine oxidoreductase (XOR) is associated with a worse prognosis in patients with serous ovarian carcinoma. Gynecol Oncol, 2012. 124(2): p. 311-8.
[37]
Yossepowitch, O., et al., Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol, 2007. 178(4 Pt 1): p. 1238-43; discussion 1243-4.
[38]
Kuo, C. F., et al., Increased risk of cancer among gout patients: a nationwide population study. Joint Bone Spine, 2012. 79(4): p. 375-8.
[39]
R. F. Anderson, K. B. Patel, K. Reghebi & S. A. Hill. Conversion of xanthine dehydrogenase to xanthine oxidase as a possible marker for hypoxia in tumours and normal tissues. Br. J. Cancer.1989. 60:p.193-7.
[40]
Rodrigues, P., et al., Identification of candidate polymorphisms on stress oxidative and DNA damage repair genes related with clinical outcome in breast cancer patients. Int J Mol Sci, 2012. 13(12): p. 16500-13.
[41]
Masaharu MURATA, Kotaro FUKUSHIMA, Tomoka TAKAO, Hiroyuki SEKI, Satoru TAKEDA, Norio WAKE. Oxidative Stress Produced by Xanthine Oxidase Induces Apoptosis in Human Extravillous Trophoblast Cells.J Reprod Dev. 2013; 59(1): 7–13.
[42]
Pierre-Yves Desprez, Tomoki Sumida, and Jean-Philippe Copp´e. Helix-Loop-Helix Proteins in Mammary Gland Development and Breast Cancer. Journal of Mammary Gland Biology and Neoplasia, 2003. 8(2): p. 14.
[43]
Napoli, J. L. Retinoic acid biosynthesis and metabolism. FASEB J. 1996. 10: 993–1001.
[44]
Taibi, G., et al., Low levels of both xanthine dehydrogenase and cellular retinol binding protein are responsible for retinoic acid deficiency in malignant human mammary epithelial cells. Ann N Y Acad Sci, 2009. 1155: p. 268-72.
[45]
Fini, M. A., et al., Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase. J Cell Biochem, 2008. 105(4): p. 1008-26.
[46]
Fini, M. A., et al., Contribution of xanthine oxidoreductase to mammary epithelial and breast cancer cell differentiation in part modulates inhibitor of differentiation-1. Mol Cancer Res, 2011. 9(9): p. 1242-54.
[47]
Cook W, Chu R, Saksela M, Raivio K, Yeldandi A. Differential immunohistochemical localization of xanthine oxidase in normal and neoplastic human breast epithelium. Int J Oncol. 1997.11(5):1013-7.
[48]
Cai, J., Superoxide in Apoptosis. MITOCHONDRIAL GENERATION TRIGGERED BY CYTOCHROME c LOSS. Journal of Biological Chemistry, 1998. 273(19): p. 11401-11404.
[49]
EYAL GOTTLIEB, M.G.V.H., AND CRAIG B. THOMPSON, Bcl-xL Prevents the Initial Decrease in Mitochondrial Membrane Potential and Subsequent Reactive Oxygen Species Production during Tumor Necrosis Factor Alpha-Induced Apoptosis. Molecular and cellular biology, 2000. 20(15): p. 5680–9.
[50]
Meeran, S. M., S. Katiyar, and S. K. Katiyar, Berberine-induced apoptosis in human prostate cancer cells is initiated by reactive oxygen species generation. Toxicol Appl Pharmacol, 2008. 229(1): p. 33-43.
[51]
Van Den Broeck, A., et al., Activation of a Tip60/E2F1/ERCC1 network in human lung adenocarcinoma cells exposed to cisplatin. Carcinogenesis, 2012. 33(2): p. 320-5.
[52]
Turnbull, C. L., et al., In vitro stability of APC gene sequences and the influence of DNA repair status. Mutagenesis, 2012. 27(2): p. 233-8.
[53]
Castiglia, D, et al, Concomitant activation of Wnt pathway and loss of mismatch repair function in human melanoma. Genes Chromosomes Cancer, 2008. 47(7): p. 614-24.
[54]
Kodigepalli, K. M., et al., SnoN/SkiL expression is modulated via arsenic trioxide-induced activation of the PI3K/AKT pathway in ovarian cancer cells. FEBS Lett, 2013. 587(1): p. 5-16.
[55]
Reuther, S., et al., Association between SNPs in defined functional pathways and risk of early or late toxicity as well as individual radiosensitivity. Strahlenther Onkol, 2015. 191(1): p. 59-66.
[56]
Nozik-Grayck, E., et al., Lung EC-SOD overexpression attenuates hypoxic induction of Egr-1 and chronic hypoxic pulmonary vascular remodeling. Am J Physiol Lung Cell Mol Physiol, 2008. 295(3): p. L422-30.
[57]
Hartney, T., et al., Xanthine oxidase-derived ROS upregulate Egr-1 via ERK1/2 in PA smooth muscle cells; model to test impact of extracellular ROS in chronic hypoxia. PLoS One, 2011. 6(11): p. e27531.
[58]
Ohtsubo, T., et al., Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules. Hypertension, 2009. 54(4): p. 868-76.
[59]
Scheepers LE, Wei FF, Stolarz-Skrzypek K, Malyutina S, Tikhonoff V, Thijs L, Salvi E, Barlassina C, Filipovský J, Casiglia E, Nikitin Y, Kawecka-Jaszcz K, Manunta P, Cusi D, Boonen A, Staessen JA, Arts IC. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. J Hypertension. 2016. [Epub ahead of print].
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186